Evidence map›Paper›PMID 16129567›Full record

Trial reportDrug and alcohol dependence2006

High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities.

Jennifer V Campbell, Holly Hagan, Mary H Latka, Richard S Garfein, Elizabeth T Golub, Micaela H Coady, David L Thomas, Steffanie A Strathdee, STRIVE Project

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00391482 (Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00391482 phase2 / phase3completednot on this map

Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users

TypeinterventionalSponsorNational Institute on Drug Abuse (NIDA)Ran2002 to 2005Enrolled750ConditionsHepatitis C, HIV InfectionsArmsPeer Mentoring Intervention for HCV-Infected IDUs
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Integrating Care for Patients With Chronic Liver Disease and Mental Health and Substance Use Disorders.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2018
    Article
  15. Article
  16. Is Moderate Alcohol Consumption Safe for Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Jennifer V CampbellHIV/AIDS Epidemiology Program, Public Health-Seattle & King County, 106 Prefontaine Place South, Seattle, WA 98104, USA. jennifer.campbell@metrokc.gov
Holly Hagan
Mary H Latka
Richard S Garfein
Elizabeth T Golub
Micaela H Coady
David L Thomas
Steffanie A Strathdee
STRIVE Project
New York Academy of Medicine · USUniversity of California, San Diego · USJohns Hopkins Medicine · USJohns Hopkins University · USNational Development and Research Institutes · USPublic Health – Seattle & King County · US

Funding

Reduce Transmission Risks &Improve HCV Treatment AccessR01DA014499 · NIDA · JOHNS HOPKINS UNIVERSITY · PI STRATHDEE, STEFFANIE A · 2001 to 2004
$3.8M
NIDA NIH HHS DA14499NIDA NIH HHS R01 DA014499
6 · The paper itself

Abstract

Injection drug users (IDUs) acquire the majority of new hepatitis C virus (HCV) infections and frequently use alcohol. Alcohol abuse accelerates liver disease among HCV-infected persons, can reduce the effectiveness of treatment for HCV infection and may be a contraindication for HCV treatment. HCV seropositive, HIV-negative IDUs aged 18-35 years in Baltimore, New York City and Seattle who were enrolled in a behavioral risk-reduction intervention trial underwent computerized self-interviews to assess baseline alcohol use and dependence and medical history. We measured problem alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT) scale. Of 598 participants, 84% responded "false" to: "it is safe for a person with HCV to drink alcohol". Problem drinking, defined as score > or =8 on AUDIT, was identified in 37%. Correlates of scoring > or =8 on AUDIT included homelessness, male gender, primarily injecting speedballs, having injected with used needles, prior alcohol treatment and depression. Although most HCV seropositive IDUs in our sample appear informed about their increased risk of liver disease from alcohol, two-fifths screened positive for problem alcohol use. These findings underscore the importance of referring HCV-positive persons to effective alcohol treatment programs to reduce future liver damage and improve eligibility for and effectiveness of treatment of HCV.

Indexed as

AdolescentAdultAlcoholismCatchment Area, HealthFemaleFollow-Up StudiesHepatitis CHepatitis C AntibodiesHIV SeropositivityHumansMalePrevalenceRisk-TakingSubstance Abuse, IntravenousUnited StatesHepatitis C Antibodies

Identifiers

PMID16129567
PMCPMC2196223
OpenAlexW2001899175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.